Posted by Michael Wonder on 17 Aug 2020
Janssen and others have appealed NICE's decision to reject abiraterone acetate for patients with for high risk hormone-sensitive metastatic prostate cancer
17 August 2020 - The appeal panel will convene on 3 September and 4 September to hear oral representations from the three appellants.
NICE has received three appeals against the Final Appraisal Document for abiraterone acetate from the following organisations:
- British Uro-Oncology Group
- Janssen-Cilag Ltd UK
- Prostate Cancer UK and Tackle Prostate Cancer (joint appeal)
